GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000697920 | Oral cavity | OSCC | response to oxidative stress | 273/7305 | 446/18723 | 8.35e-22 | 1.65e-19 | 273 |
GO:003450415 | Oral cavity | OSCC | protein localization to nucleus | 193/7305 | 290/18723 | 1.22e-21 | 2.35e-19 | 193 |
GO:01400145 | Oral cavity | OSCC | mitotic nuclear division | 191/7305 | 287/18723 | 1.99e-21 | 3.70e-19 | 191 |
GO:190336220 | Oral cavity | OSCC | regulation of cellular protein catabolic process | 174/7305 | 255/18723 | 2.04e-21 | 3.70e-19 | 174 |
GO:200124220 | Oral cavity | OSCC | regulation of intrinsic apoptotic signaling pathway | 123/7305 | 164/18723 | 5.71e-21 | 9.77e-19 | 123 |
GO:000660520 | Oral cavity | OSCC | protein targeting | 204/7305 | 314/18723 | 6.78e-21 | 1.13e-18 | 204 |
GO:001623610 | Oral cavity | OSCC | macroautophagy | 192/7305 | 291/18723 | 7.01e-21 | 1.14e-18 | 192 |
GO:190332020 | Oral cavity | OSCC | regulation of protein modification by small protein conjugation or removal | 165/7305 | 242/18723 | 2.52e-20 | 3.99e-18 | 165 |
GO:000640118 | Oral cavity | OSCC | RNA catabolic process | 184/7305 | 278/18723 | 2.71e-20 | 4.19e-18 | 184 |
GO:003164720 | Oral cavity | OSCC | regulation of protein stability | 193/7305 | 298/18723 | 1.30e-19 | 1.95e-17 | 193 |
GO:005065714 | Oral cavity | OSCC | nucleic acid transport | 120/7305 | 163/18723 | 2.31e-19 | 3.18e-17 | 120 |
GO:005065814 | Oral cavity | OSCC | RNA transport | 120/7305 | 163/18723 | 2.31e-19 | 3.18e-17 | 120 |
GO:005165610 | Oral cavity | OSCC | establishment of organelle localization | 239/7305 | 390/18723 | 2.46e-19 | 3.31e-17 | 239 |
GO:00447728 | Oral cavity | OSCC | mitotic cell cycle phase transition | 255/7305 | 424/18723 | 5.29e-19 | 6.98e-17 | 255 |
GO:005123614 | Oral cavity | OSCC | establishment of RNA localization | 121/7305 | 166/18723 | 6.38e-19 | 8.24e-17 | 121 |
GO:003315718 | Oral cavity | OSCC | regulation of intracellular protein transport | 155/7305 | 229/18723 | 1.05e-18 | 1.28e-16 | 155 |
GO:000609118 | Oral cavity | OSCC | generation of precursor metabolites and energy | 286/7305 | 490/18723 | 1.45e-18 | 1.71e-16 | 286 |
GO:000640218 | Oral cavity | OSCC | mRNA catabolic process | 156/7305 | 232/18723 | 2.13e-18 | 2.37e-16 | 156 |
GO:190382920 | Oral cavity | OSCC | positive regulation of cellular protein localization | 179/7305 | 276/18723 | 2.20e-18 | 2.41e-16 | 179 |
GO:004325420 | Oral cavity | OSCC | regulation of protein-containing complex assembly | 255/7305 | 428/18723 | 2.94e-18 | 3.15e-16 | 255 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TG | SNV | Missense_Mutation | rs201480815 | c.3416N>T | p.Ser1139Leu | p.S1139L | P01266 | protein_coding | tolerated(0.14) | benign(0) | TCGA-A1-A0SK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
TG | SNV | Missense_Mutation | | c.4662G>T | p.Trp1554Cys | p.W1554C | P01266 | protein_coding | deleterious(0.01) | benign(0.123) | TCGA-A1-A0SP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
TG | SNV | Missense_Mutation | | c.4882N>T | p.Asp1628Tyr | p.D1628Y | P01266 | protein_coding | deleterious(0) | possibly_damaging(0.861) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
TG | SNV | Missense_Mutation | | c.3133N>A | p.Gly1045Arg | p.G1045R | P01266 | protein_coding | tolerated(0.13) | benign(0.007) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD |
TG | SNV | Missense_Mutation | | c.5223N>C | p.Gln1741His | p.Q1741H | P01266 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD |
TG | SNV | Missense_Mutation | rs773795717 | c.4645C>T | p.Arg1549Trp | p.R1549W | P01266 | protein_coding | deleterious(0.05) | benign(0.232) | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD |
TG | SNV | Missense_Mutation | novel | c.1093N>A | p.Ala365Thr | p.A365T | P01266 | protein_coding | tolerated(0.44) | benign(0) | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
TG | SNV | Missense_Mutation | rs146594373 | c.4268N>A | p.Arg1423His | p.R1423H | P01266 | protein_coding | tolerated(0.55) | benign(0.001) | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
TG | SNV | Missense_Mutation | | c.746G>A | p.Gly249Asp | p.G249D | P01266 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | | CR |
TG | SNV | Missense_Mutation | | c.3746N>T | p.Cys1249Phe | p.C1249F | P01266 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | RETINOIDS | | 12182039 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | FDG | FLUDEOXYGLUCOSE-F18 | 10452315 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | BISPECIFIC ANTIBODY | | 10433080 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | PHENYTOIN | PHENYTOIN | 3935423 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | PREDNISONE | PREDNISONE | 2745931 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | ALL-TRANS-RETINOIC ACID | | 10946899 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | TGFBETA1 | | 10770487,10194419 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | RETINOIC ACID | | 11563543 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | PREDNISOLONE | PREDNISOLONE | 3427792,8636270 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | AMIODARONE | AMIODARONE | 8778159 |